introduCtion. The aim of the study was to retrospectively evaluate the efficacy of intravitreal injections of bevacizumab in a large group of diabetic macular edema (DME) patients. MateriaLs and Methods. One hundred patients (125 eyes) suffering from diabetes type 1 or 2 and DME were treated with two or three monthly 1.25-mg intravitreal injections of bevacizumab. resuLts. The mean (SD) best correct visual acuity (BCVA) before treatment was 63.8 (± 26.2) letters. At months 1, 2, and 3 the mean change (SE) in BCVA from baseline was +4.4 (± 0.49), +4.9 (0.38), and +3.1 (± 0.39) letters, respectively. The mean macular retinal thickness dropped from 457 (± 183) microns to 308 (± 122) microns after three months. The improvement of retinal morphology in optical coherence tomography was evident: a decrease in the number of intraretinal cysts and a generalised shrinkage of retinal macular edema. There were no serious adverse effects of the treatment. ConCLusion. The majority of patients with DME showed an improvement in visual acuity, particularly after the first injection of bevacizumab. Bevacizumab therapy is an interesting alternative to DME treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.